Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Oh CY, Klatt MG, Bourne C, Dao T, Dacek MM, Brea EJ, Mun SS, Chang AY, Korontsvit T, Scheinberg DA.

Cancer Immunol Res. 2019 Dec;7(12):1984-1997. doi: 10.1158/2326-6066.CIR-19-0056. Epub 2019 Sep 20.

PMID:
31540894
2.

Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.

Dao T, Mun SS, Scott AC, Jarvis CA, Korontsvit T, Yang Z, Liu L, Klatt MG, Guerreiro M, Selvakumar A, Brea EJ, Oh C, Liu C, Scheinberg DA.

Oncoimmunology. 2019 Apr 15;8(7):1570778. doi: 10.1080/2162402X.2019.1570778. eCollection 2019.

3.

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.

Choi H, Deng J, Li S, Silk T, Dong L, Brea EJ, Houghton S, Redmond D, Zhong H, Boiarsky J, Akbay EA, Smith PD, Merghoub T, Wong KK, Wolchok JD.

Cell Rep. 2019 Apr 16;27(3):806-819.e5. doi: 10.1016/j.celrep.2019.03.066.

4.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A.

JCI Insight. 2018 Nov 15;3(22). pii: 125568. doi: 10.1172/jci.insight.125568. No abstract available.

5.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A.

JCI Insight. 2017 Mar 23;2(6):e90196. doi: 10.1172/jci.insight.90196. Erratum in: JCI Insight. 2018 Nov 15;3(22):.

6.

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.

Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A.

Oncotarget. 2017 Feb 21;8(8):14017-14028. doi: 10.18632/oncotarget.14876.

7.

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, Rosen N, Lowe SW, Scheinberg DA.

Cancer Immunol Res. 2016 Nov;4(11):936-947. Epub 2016 Sep 28.

8.

Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.

Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA.

Oncoimmunology. 2016 Aug 3;5(9):e1211221. eCollection 2016.

9.

Deconvoluting hepatic processing of carbon nanotubes.

Alidori S, Bowman RL, Yarilin D, Romin Y, Barlas A, Mulvey JJ, Fujisawa S, Xu K, Ruggiero A, Riabov V, Thorek DL, Ulmert HD, Brea EJ, Behling K, Kzhyshkowska J, Manova-Todorova K, Scheinberg DA, McDevitt MR.

Nat Commun. 2016 Jul 29;7:12343. doi: 10.1038/ncomms12343.

10.

Opportunities and challenges for TCR mimic antibodies in cancer therapy.

Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA.

Expert Opin Biol Ther. 2016 Aug;16(8):979-87. doi: 10.1080/14712598.2016.1176138. Epub 2016 Apr 27. Review.

11.

T cell receptor mimic antibodies for cancer therapy.

Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA.

Oncoimmunology. 2015 Jun 1;5(1):e1049803. eCollection 2016. Review.

12.

Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.

Mondello P, Pitini V, Barresi V, Brea EJ, Di Mirto C, Arrigo C, Cuzzocrea S, Mian M.

Exp Hematol Oncol. 2016 Jan 6;5:1. doi: 10.1186/s40164-015-0030-1. eCollection 2015.

13.

Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.

Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HL.

J Mol Biol. 2016 Jan 16;428(1):194-205. doi: 10.1016/j.jmb.2015.12.002. Epub 2015 Dec 11.

14.

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.

Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA.

Blood. 2014 May 22;123(21):3296-304. doi: 10.1182/blood-2014-01-549022. Epub 2014 Apr 10.

15.

Solid-state NMR analysis of membrane proteins and protein aggregates by proton detected spectroscopy.

Zhou DH, Nieuwkoop AJ, Berthold DA, Comellas G, Sperling LJ, Tang M, Shah GJ, Brea EJ, Lemkau LR, Rienstra CM.

J Biomol NMR. 2012 Nov;54(3):291-305. doi: 10.1007/s10858-012-9672-z. Epub 2012 Sep 18.

Supplemental Content

Support Center